Mutations in this gene are associated with poor outcomes.4 Flt3 mutations can be classified into two types: internal tandem duplications of 3 to over 100 amino acids in the juxtamembrane domain (Flt3/ITD) and point mutations in the tyrosine kinase domain (Flt3/KD).2,4,5 In this mini-review, we focused on these markers for the purpose of treating AML patients by inhibiting the Flt3 tyrosine kinase domain and blocking TIM-3 signaling. The gene discussed is HAVCR2; the disease is acute myeloid leukemia.